Clinical trial NCT04534192: Investigating the Safety and Efficacy of the Treatment With the Non-compliant Jade Balloon in TASC C and D Athero-occlusive Infra-inguinal Disease in Patients With Chronic Limb Threatening Limb Ischemia From SingaporE
Official title: Physician Initiated, Prospective, Non-randomized Single-centre, Single-arm Trial, Investigating the Safety and Efficacy of the Treatment With the Non-compliant Jade Balloon in TASC C and D Athero-occlusive Infra-inguinal Disease in Patients With Chronic Limb Threatening Limb Ischemia From SingaporE (PINNACLE)
Study type: INTERVENTIONAL
Overall status: UNKNOWN
Phase: NA
Conditions: Critical Limb Ischemia
Peripheral Artery Disease
Keywords: non-compliant high pressure balloon
JADE
Lead sponsor: Singapore General Hospital
Sponsor class: OTHER
Collaborators: name: National University Hospital, Singapore
First posted: 2020-09-01
Enrollment: 50
Sex: ALL
Minimum age (years): 40
Standard ages: ADULT
OLDER_ADULT
Accepts healthy volunteers: no
Allocation: NA
Intervention model: SINGLE_GROUP
Intervention model description: Non-randomized, single arm
Primary purpose: TREATMENT

Brief summary: The objective of this clinical study is to evaluate the 6-month safety and performance outcome of the non-compliant high pressure JADE balloon for the treatment of infrainguinal stenotic occlusive or stenotic TASC C \& D lesions in patients with chronic limb threatening ischemia.

Detailed description: Pulsatile straight line blood flow to the foot is required to aid wound healing in the setting of chronic limb threatening ischaemia (CLTI). Patients with CLTI usually present with infra-popliteal arterial occlusions and endovascular therapies to restore blood flow are often preferred considering their inherently less invasive nature and because of multiple patient background comorbidities or absence of a suitable vein conduit in these patients. Below The Knee (BTK) plain balloon angioplasty (POBA) remains the only viable "standard of care" in the management of long "Real World" BTK Lesions. However tibial angioplasty is plagued by high rate of re-occlusion/stenosis because of barotrauma caused by the intra-arterial ballooning and subsequent development of neointimal hyperplasia. Devices coated with paclitaxel have been used successfully to limit restenosis by inhibiting the biologic pathway that leads to intimal hyperplasia. However, a recent formal systematic review and study-level meta-analysis of randomized controlled trials investigating treatment of the infra-popliteal arteries with paclitaxel-coated balloons compared with conventional balloon angioplasty for critical limb ischemia (CLI) was recently published showing amputation-free survival was significantly worse in use of paclitaxel coated balloons compared to plain angioplasty. Furthermore current poor patency seen in BTK angioplasty is likely contributed in part by small vessel size and poor luminal gain after standard semi-compliant POBA. Vessel Preparation and Optimising POBA with High Pressure, Non-Compliant balloons may help achieve Luminal Gain for rapid and sustained flow for wound healing. The objective of this clinical study is to evaluate the 6-month safety and performance outcome of the non-compliant high pressure JADE balloon for the treatment of infrainguinal stenotic occlusive or stenotic TASC C \& D lesions in patients with chronic limb threatening ischemia.

Eligibility criteria: Inclusion Criteria:

1. Age of subject is \> 40 years old. Patient covered by MediShield insurance as provided by Singapore government.
2. Patient has critical limb ischemia, presenting a score from 4 to 6 following the Rutherford classification
3. Patients must agree to return for all required post-index procedure follow-up visits.
4. Patient understands the nature of the procedure and provides written informed consent, prior to enrolment in the study
5. Patient has a projected life expectancy of at least 12 months and has not suffered a myocardial infarction within past 30 days

Angiographic Inclusion Criteria:

1. De novo and post-PTA re-stenotic lesions located in the superficial femoral, popliteal and tibial arteries suitable for endovascular therapy
2. The target lesion is located within the native SFA/popliteal/tibial artery
3. The length of the target lesion(s) is \> 100mm and considered as TASC C or D lesion according to the TASC II classification.
4. The target lesion has angiographic evidence of stenosis \> 50% or occlusion, which has been passed with standard guidewire manipulation and no other adjunctive devices have been used to prepare the lesion (example scoring balloon, rotablator, atherectomy device)
5. Target vessel diameter visually estimated is \>1.5mm and \< 6.5mm below the groin
6. Prior to enrolment, the guidewire has crossed the target lesion
7. Lesions in the treated segment may be continuous or may have gaps present between stenoses and occlusions
8. Inflow iliac, common femoral artery lesions can be treated during the same procedure using standard angioplasty and/or approved device/open surgery. These inflow lesions must be treated first prior to consideration of treatment of the distal lying lesions. The patient can be enrolled if the inflow lesions are treated with good embolization)
9. There is angiographic evidence of at least one- vessel-runoff through the ankle and into the foot, irrespective of whether or not outflow was re- established by means of previous endovascular intervention

Exclusion Criteria:

1. Patient is permanently wheel-chair bound or bedridden
2. Presence of a stent in the target lesion(s) that was placed during a previous procedure
3. The intervention is being performed in preparation for a planned amputation.
4. Untreated flow-limiting inflow lesions
5. Any previous surgery in the target vessel (including prior ipsilateral crural bypass)
6. Previous bypass surgery in the same limb
7. Patients with a history of Myocardial Infarction (MI), thrombolysis or angina within 30 days prior-index procedure.
8. Patients with a history of major disabling stroke within 3 months prior index procedure.
9. Patients with any type of previous or planned surgical or interventional procedure within 15 days prior- and/or within 30 days post-index procedure.
10. Untreatable lesion located at the distal outflow arteries
11. Patients with uncorrected bleeding disorders
12. Aneurysm located at the level of the SFA/popliteal artery
13. Non-atherosclerotic disease resulting in occlusion (e.g. embolism, Buerger's disease, vasculitis)
14. Any condition which prevents patient from complying with the study protocol or if patient has a life expectancy of \<1yr.
15. Major distal amputation (above the transmetatarsal) in the study limb or non-study limb
16. Patients with a presence or history of severe renal failure (Glomerular Filtration Rate (GFR) ≤ 30 ml/min) and is not dialysis dependent.
17. Neurotrophic ulcer or heel pressure ulcer or ulcer potentially involving calcaneus (index limb)
18. Episode of acute limb ischaemia within the previous 1 month
19. Use of thrombectomy, cutting balloon, lithotripsy, atherectomy or laser devices during procedure
20. Any patient considered to be hemodynamically unstable at onset of procedure
21. Patients with a known hypersensitivity or contraindication to aspirin, heparin, clopidogrel, or other anticoagulant/anti-platelet therapies or sensitivity to contrast media that cannot be adequately premedicated.
22. The patient is currently breast-feeding, pregnant or intends to become pregnant.
23. Subject receiving immunosuppression therapy, or has known serious immunosuppressive disease (e.g., human immunodeficiency virus), or has severe autoimmune disease that requires chronic immunosuppressive therapy (e.g., systemic lupus erythematosus, etc.) The patient should also not receive inhibitors of CYP3A (such as Itraconazole, and Erythromycin), or inducers of CYP3A (such as Rifampin) within 90 days following the procedure.
24. Patient is participating in another research study of a device, medication, biologic or other agent within 30 days which could in the opinion of the investigator affect the results of this study
25. Patients with any contraindications as mentioned in the Instructions for Use (IFU) of the Investigational Device.

Primary outcomes:
measure: Freedom from Major Adverse Events
timeFrame: 30 days post-index procedure
measure: Performance Primary Endpoint
timeFrame: 6 months post-index procedure
Secondary outcomes:
measure: Primary patency rate
timeFrame: 6- and 12-month post-index procedure
measure: Technical success
timeFrame: Immediately post-op
measure: Freedom from clinically-driven TLR
timeFrame: 12-month post-index procedure
measure: Clinical success at follow-up
timeFrame: 6 and 12 months post index procedure
measure: Wound healing
timeFrame: 6 months post-index procedure
measure: Freedom from major target limb amputation (above ankle)
timeFrame: 6 months and 12 months post-index procedure
measure: Improvements in walking
timeFrame: 3, 6 and 12 months post-index procedure.
measure: Freedom from serious adverse events
timeFrame: 3, 6 and 12 months post-index procedure.
Other outcomes:
Locations:
city: Singapore
country: Singapore
facility: Singapore General Hospital
Study officials:
affiliation: Singapore General Hospital
name: Tjun Yip Tang, MD
role: PRINCIPAL_INVESTIGATOR
References: